美国Gen-Probe 
Gen-Probe公司（美国分子生物学检测方法创始公司之一，是FDA指定的为美国血库作检测的公司），位于美国圣地亚哥，是一个在开发、制造和商业化基于它的专利基因探针技术的诊断产品的公认的世界领导公司。

　　在用基因探针试验检测微生物的领域中，公司已经取得41个FDA许可，包括那些可致性传播疾病、肺结核、咽喉炎、肺炎和真菌感染等。

　　Gen-Probe现在正在开发病毒核酸试验用于筛查血源中的HIV-1、丙肝和乙肝病毒，并同此领域的世界上领导公司如bioMérieux,Chiron, 和Bayer保持合作关系。

       

Gen-Probe Incorporated (NASDAQ: GPRO) is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) used primarily to diagnose human diseases and screen donated human blood. NATs harness the power of biotechnology to detect diseases more rapidly and/or accurately than older testing methods, and have therefore become one of the fastest-growing segments of the in vitro diagnostics industry.

Gen-Probe markets a broad portfolio of products that use the Company's patented technologies to detect infectious microorganisms, including those causing sexually transmitted diseases (STDs), tuberculosis, strep throat, pneumonia and fungal infections. Gen-Probe's key clinical diagnostics products include the APTIMA COMBO 2® and PACE® assays, which are used to detect the common STDs Chlamydia and gonorrhea.

In blood screening, Gen-Probe developed and manufactures the PROCLEIX® assay, which is used to detect HIV-1 and the hepatitis C virus (HCV) in donated human blood; the PROCLEIX ULTRIO® assay, which detects the hepatitis B virus in addition to HIV-1 and HCV; and the PROCLEIX WNV (West Nile virus) assay. Gen-Probe's blood screening products are marketed worldwide by Chiron, a business unit of Novartis Vaccines and Diagnostics, Inc.

Gen-Probe also has a robust development pipeline. For example, the Company is developing NATs to detect prostate cancer, drug-resistant hospital infections, and human papillomavirus, which causes cervical cancer. In addition, Gen-Probe is working with General Electric and Millipore to develop NATs that detect microorganisms that commonly contaminate industrial processes.

Several of Gen-Probe's current and future molecular diagnostic tests can be performed on the Company's TIGRIS® instrument, the only fully automated, high-throughput NAT system for diagnostics and blood screening.

Gen-Probe is headquartered in San Diego and employs approximately 1,000 people.